Li Caizheng, Zheng Li
Institute of Clinical Pharmacology, West China Hospital, Sichuan University, Chengdu, 610041, China.
Int J Hematol. 2014 Dec;100(6):529-39. doi: 10.1007/s12185-014-1660-5. Epub 2014 Sep 18.
The discovery and application of thrombopoietin (TPO) and thrombopoietin receptor (TPOR) agonists have changed the clinical treatment of thrombocytopenia. These compounds exert favorable clinical effects without the adverse events caused by traditional treatments (e.g., corticosteroids, immunoglobulins, monoclonal antibodies and splenectomy). This review provides a synopsis of new agents that boost platelet production, especially the TPOR agonists, and highlights their pharmacological characteristics and clinical applications.
血小板生成素（TPO）和血小板生成素受体（TPOR）激动剂的发现与应用改变了血小板减少症的临床治疗。这些化合物产生良好的临床效果，且无传统治疗（如皮质类固醇、免疫球蛋白、单克隆抗体和脾切除术）所引起的不良事件。本综述概述了促进血小板生成的新型药物，尤其是TPOR激动剂，并重点介绍了它们的药理学特性和临床应用。
